The Tropion-Lung01 Phase III Trial Reveals that Datopotamab Deruxtecan Significantly Enhanced Overall Survival in Advanced Nonsquamous NSCLC Patients Compared to Chemotherapy
The high-level overall survival (OS) results from the TROPION-Lung01 Phase III trial, which had previously met the dual primary endpoint of progression-free survival (PFS), showed that datopotamab deruxtecan (Dato-DXd) was numerically favored over docetaxel in the overall population of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who had received at least one prior line of therapy. However, the survival results did not achieve statistical significance in the ...